False FDA Clearance Claims: Unapproved Devices Sold as Authorized

Medical device FDA clearance misrepresentation means selling a device on a false claim about what the Food and Drug Administration authorized. The discrepancy may be an invented clearance, an exemption the manufacturer cannot support, or an intended use the agency never cleared. A regulatory employee may hold the FDA correspondence. A distributor may hold the manufacturer’s assurances and the emails questioning them. The useful comparison is the device and use offered to customers against the authorization behind the offer, followed through to the procedure billed to the government.

FDA Cleared Versus Approved Starts With the Actual Device

FDA cleared and FDA approved describe different decisions. Clearance rests on substantial equivalence to a legally marketed predicate device, including its intended use and technological characteristics. Premarket approval requires reasonable assurance of safety and effectiveness under the labeled conditions of use. Presenting clearance as official approval promises more than the agency decided.

Registration and listing identify an establishment or product in the agency’s system. They do not establish approval or permission to market that product. A registration number presented as proof of official approval is misleading.

The authorization also has to match the product being sold. A significant change in design, materials or manufacturing that could significantly affect safety or effectiveness, or a major change in intended use, can require a new submission. An earlier clearance can describe a different version of the product.

The False Clearance Statement Can Reach the Buyer First

A false authorization claim can appear in a public sales announcement or in correspondence between a manufacturer and its distributor. The hospital or surgery center buys the device, a physician uses it, and the institution bills for the procedure. Different people hold each part of that transaction.

The whistleblower’s complaint concerning Biocompatibles’ LC Bead accused RITA of falsely claiming FDA clearance in a press release. The announcement claimed clearance for embolization of hypervascular tumors and arteriovenous malformations. The complaint alleged the product had no clearance at the time:

Acclarent Sold a Different Intended Use

Acclarent’s Stratus device had clearance as a sinus spacer for use with saline. The dispute concerned its use to deliver a steroid. In its civil settlement announced in July 2016, Acclarent agreed to pay $18 million to resolve allegations that marketing and distributing the device for drug delivery caused healthcare providers to submit false claims to Medicare and other federal health care programs.

The court’s account of the separate criminal case supplies the regulatory sequence. Acclarent asked to change the instructions so users could inject saline or another therapeutic agent. The Food and Drug Administration rejected that request and said the changed intended use would require a new submission. The jury found that the executives had distributed the device without the required clearance.

The company had a cleared product. It was selling a use the agency had refused to clear.

CareFusion and Instrumed Claimed an Exemption They Could Not Support

The CareFusion and Instrumed cases show how an unsupported authorization claim can survive repeated challenges inside the supply chain. Instrumed relied on the pre-amendment exception, claiming its devices qualified for treatment reserved for products legally marketed before May 28, 1976. The claimed history was the company’s explanation for selling without obtaining new FDA clearance.

CareFusion agreed to a $3.3 million civil settlement in 2019 and admitted distributing devices for which the manufacturer had neither the required authorization nor adequate evidence supporting the exemption. It bought the devices and resold them to hospitals and other providers. Some went into procedures billed to Medicare and Medicaid.

Avalign Technologies and its subsidiary Instrumed International agreed to a $9.5 million settlement later that year. Their admissions included an email from Instrumed’s head of Quality and Regulatory Affairs:

The company’s own regulatory head said it could not claim the exemption. The devices kept selling.

CareFusion repeatedly told Instrumed that the evidence was insufficient. That evidence consisted of excerpts from the original manufacturer’s catalog and an affidavit from an Instrumed employee. Instrumed never provided a satisfactory affidavit. The Food and Drug Administration eventually issued a warning letter rejecting the claimed status, and Instrumed discontinued sales and recalled the products.

Patients received care using uncleared devices in spinal surgeries, circumcisions and other procedures, and providers billed Medicare and Medicaid for that care. Taxpayers were being asked to pay for procedures using devices the companies had no basis to sell. A whistleblower started the case, and the government joined it.

The distributor held more than a supplier’s assurance. It held the evidence offered for that assurance and its own objections to it. For someone in procurement or regulatory affairs, that exchange can explain both what the business represented and what people inside it knew.

Aesculap’s Clearance Documents Were Forged

Aesculap’s authorization problem concerned the ELAN-4 Air Drill and the JS Series SterilContainer S2. Under its criminal non-prosecution agreement, described in the Justice Department’s November 2025 announcement, the company admitted distributing those devices without FDA clearance. The employee responsible for obtaining clearance never submitted documentation to the agency and forged documents making both devices appear cleared.

Advanced Bionics Put the Test Configuration at Issue

Advanced Bionics agreed in December 2022 to pay more than $12 million to resolve allegations about radio-frequency emissions testing for its Neptune and Naida cochlear implant processors. The alleged misrepresentations appeared in premarket approval applications to the Food and Drug Administration. The company represented that the processors met an internationally recognized emissions standard.

The Justice Department alleged that the company failed to test using the worst-case configurations the standard required and improperly shielded components that generated emissions. The testing measured emissions that could interfere with other devices using the radio spectrum.

The government also alleged that Advanced Bionics sought reimbursement from Medicare, Medicaid and other federally funded programs for the devices. A former company engineer brought the whistleblower case.

The engineer’s position matters to the evidence. A person familiar with the setup can compare the testing standard, the components exposed during the test, the results and the representation in the application. A statement that the product passed a standard can conceal the way it was tested.

How Does the FDA Representation Reach a Medicare Claim?

The connection runs through the device sale, the clinical use and the provider’s request for payment. In CareFusion and Instrumed, the government expressly identified procedures using the devices and claims submitted for those procedures. In Acclarent, the civil allegations said the manufacturer caused providers to submit false claims through its marketing and distribution.

A sales assurance about FDA status can reach the purchasing decision before anyone in billing sees it.

For implanted devices, the cost usually sits inside payment for a procedure or hospital stay. Hospital outpatient payments package implantable devices into the service, while inpatient payments absorb device costs into the payment for the stay. Device information may appear on a claim even when there is no separate payment for the implant. We follow the institution’s bill as well as the manufacturer’s sale.

A 2020 analysis in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, emphasizes the practical effect of a false statement on payment. Here, that means connecting the authorization story to what the hospital bought, what the physician used and what the program was asked to pay. The internal correspondence can explain how the false statement traveled that distance.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

What Evidence Proves a False FDA Clearance Claim?

The useful evidence connects the exact representation to the device, the recipient, the company’s knowledge and the resulting claim.

The clearance correspondence, engineering test results and distributor’s objections may sit in different departments, while the hospital holds the purchasing and billing records. We connect those records with you to establish what the company represented, what it knew and how the device reached a government-funded procedure. Your firsthand knowledge can explain the gap between the authorization file and what customers were told.

When You Know What the FDA File Really Says

If you work in regulatory affairs, engineering, distribution or hospital purchasing and know the authorization story does not match the device being sold, speak to one of our whistleblower experts about the clearance that does not match the device. We work beside you to turn that inside knowledge into a medical device whistleblower case grounded in the actual sales and claims. We bring in medical device fraud whistleblower lawyers who understand FDA submissions and provider reimbursement, and stay with you through the case.